Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma

Cancer Biology and Therapy

Volumn 16, Issue 5, 2015, Pages 743-749

  Golovine, Konstantin ^a   Makhov, Peter ^a   Naito, Sei ^a   Raiyani, Henish ^a   Tomaszewski, Jeffrey ^a   Mehrazin, Reza ^a   Tulin, Alexei ^a   Kutikov, Alexander ^a   Uzzo, Robert G ^a   Kolenko, Vladimir M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

c Met; Cancer; Piperlongumine; Renal; ROS

Indexed keywords

ANTINEOPLASTIC ALKALOID; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PIPERLONGUMINE; PIPERLONGUMINE DERIVATIVE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RNA; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; PIPERLONGUMININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PIPER LONGUM; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; GENETICS; METABOLISM; MOLECULAR MODEL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DIOXOLANES; DOWN-REGULATION; HUMANS; MALE; MICE; MODELS, MOLECULAR; PROTO-ONCOGENE PROTEINS C-MET; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84943800105     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1026511     Document Type: Article

References (41)

1. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159 (4): 1163-7; PMID: 9507823; http://dx. doi. org/10. 1016/S0022-5347(01)63541-9.
2. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173(1): 48-51; PMID: 15592023; http://dx. doi. org/10. 1097/01. ju. 0000148261. 19532. 2c.
3. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003; 4(5): 385-90; PMID: 12941198; http://dx. doi. org/10. 1007/s11864-003-0039-2.
4. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009; 27 (19): 3225-34; PMID: 19470934; http://dx. doi. org/10. 1200/JCO. 2008. 19. 9836.
5. Rini BI. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 2010; 16 (5): 1348-54; PMID: 20179240; http://dx. doi. org/10. 1158/1078-0432. CCR-09-2273.
6. Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 2013; 24(2): 343-9; PMID: 23022995; http://dx. doi. org/10. 1093/annonc/mds463.
7. Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009; 9(6): 785-93; PMID: 19496715; http://dx. doi. org/10. 1586/era. 09. 43.
8. Graveel CR, Tolbert D, Vande Woude GF. MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol 2013; 5(7); PMID: 23818496; http://dx. doi. org/10. 1101/cshperspect. a009209.
9. Harshman LC, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J 2013; 19(4): 316-23; PMID: 23867513; http://dx. doi. org/10. 1097/PPO. 0b013e31829e3c9a.
10. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15(7): 2207-14; PMID: 19318488; http://dx. doi. org/10. 1158/1078-0432. CCR-08-1306.
11. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316(5827): 1039-43; PMID: 17463250; http://dx. doi. org/10. 1126/science. 1141478.
12. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Janne PA, Engelman JA. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011; 71(3): 1081-91; PMID: 21266357; http://dx. doi. org/10. 1158/0008-5472. CAN-10-1623.
13. Bezerra DP, Pessoa C, Moraes MO, Alencar NM, Mesquita RO, Lima MW, Alves AP, Pessoa OD, Chaves JH, Silveira ER, et al. In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species. J Appl Toxicol 2008; 28 (5): 599-607; PMID: 17975786; http://dx. doi. org/10. 1002/jat. 1311.
14. Morikawa T, Matsuda H, Yamaguchi I, Pongpiriyadacha Y, Yoshikawa M. New amides and gastroprotective constituents from the fruit of Piper chaba. Planta Med 2004; 70(2): 152-9; PMID: 14994194; http://dx. doi. org/10. 1055/s-2004-815493.
15. Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: a global perspective. Pharmacol Ther 2003; 99(1): 1-13; PMID: 12804695; http://dx. doi. org/10. 1016/S0163-7258(03)00042-1.
16. Golovine KV, Makhov PB, Teper E, Kutikov A, Canter D, Uzzo RG, Kolenko VM. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate 2013; 73 (1): 23-30; PMID: 22592999; http://dx. doi. org/10. 1002/pros. 22535.
17. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011; 475 (7355): 231-4; PMID: 21753854; http://dx. doi. org/10. 1038/nature10167.
18. Ginzburg S, Golovine KV, Makhov PB, Uzzo RG, Kutikov A, Kolenko VM. Piperlongumine inhibits NFkappaB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate 2014; 74 (2): 177-86; PMID: 24151226; http://dx. doi. org/10. 1002/pros. 22739.
19. Makhov P, Golovine K, Teper E, Kutikov A, Mehrazin R, Corcoran A, Tulin A, Uzzo RG, Kolenko VM. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br J Cancer 2014; 110(4): 899-907; PMID: 24434432.
20. Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG, Kolenko VM. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 2012; 11(7): 1510-7; PMID: 22532600; http://dx. doi. org/10. 1158/1535-7163. MCT-11-0907.
21. Adams DJ, Dai M, Pellegrino G, Wagner BK, Stern AM, Shamji AF, Schreiber SL. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci U S A 2012; 109 (38): 15115-20; PMID: 22949699; http://dx. doi. org/10. 1073/pnas. 1212802109.
22. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31(2): 181-6; PMID: 23213094; http://dx. doi. org/10. 1200/JCO. 2012. 43. 3383.
23. Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 2011; 17(24): 7754-64; PMID: 21976535; http://dx. doi. org/10. 1158/1078-0432. CCR-11-1002.
24. Schoffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, et al. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int 2011; 108(5): 679-86; PMID: 21156020.
25. Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 2012; 118 (23): 5894-902; PMID: 22605650; http://dx. doi. org/10. 1002/cncr. 27582.
26. Choueiri TK, Pal SK, McDermott DF, Ramies DA, Morrissey S, Lee Y, Miles D, Holland JS, Dutcher JP. Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol 2012; suppl 5: abstr 364.
27. Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 2008; 7 (12): 1875-84; PMID: 18981733; http://dx. doi. org/10. 4161/cbt. 7. 12. 7067.
28. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006; 5: 14; PMID: 16689993; http://dx. doi. org/10. 1186/1477-3163-5-14.
29. Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science 2006; 312(5782): 1882-3; PMID: 16809515; http://dx. doi. org/10. 1126/science. 1130481.
30. Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L, Noel T, Holley AK, Zhao Y, Kiningham KK, et al. KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. Cancer Res 2013; 73 (14): 4406-17; PMID: 23674500; http://dx. doi. org/10. 1158/0008-5472. CAN-12-4297.
31. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7(2): 97-110; PMID: 15158766; http://dx. doi. org/10. 1016/j. drup. 2004. 01. 004.
32. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007; 13(2 Pt 2): 758s-63s; PMID: 17255306; http://dx. doi. org/10. 1158/1078-0432. CCR-06-1986.
33. Di Lorenzo G, Buonerba C, Biglietto M, Scognamiglio F, Chiurazzi B, Riccardi F, Carteni G. The therapy of kidney cancer with biomolecular drugs. Cancer Treat Rev 2010; 36 Suppl 3: S16-20; PMID: 21129605; http://dx. doi. org/10. 1016/S0305-7372(10)70015-3.
34. Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 2009; 115(10 Suppl): 2313-20; PMID: 19402072; http://dx. doi. org/10. 1002/cncr. 24239.
35. Husseinzadeh HD, Garcia JA. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol 2011; 6(3): 214-21; PMID: 21827395; http://dx. doi. org/10. 2174/157488411797189433.
36. Morais C, Gobe G, Johnson DW, Healy H. The emerging role of nuclear factor kappa B in renal cell carcinoma. Int J Biochem Cell Biol 2011; 43 (11): 1537-49; PMID: 21854869; http://dx. doi. org/10. 1016/j. biocel. 2011. 08. 003.
37. Oya M, Takayanagi A, Horiguchi A, Mizuno R, Ohtsubo M, Marumo K, Shimizu N, Murai M. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003; 24(3): 377-84; PMID: 12663495; http://dx. doi. org/10. 1093/carcin/24. 3. 377.
38. Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002; 99(1): 53-7; PMID: 11948491; http://dx. doi. org/10. 1002/ijc. 10303.
39. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010; 221(2): 125-38; PMID: 20225241; http://dx. doi. org/10. 1002/path. 2689.
40. Kirsanov KI, Kotova E, Makhov P, Golovine K, Lesovaya EA, Kolenko VM, Yakubovskaya MG, Tulin AV. Minor grove binding ligands disrupt PARP-1 activation pathways. Oncotarget 2014; 5(2): 428-37; PMID: 24504413.
41. Golovine K, Makhov P, Uzzo RG, Shaw T, Kunkle D, Kolenko VM. Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res 2008; 14 (17): 5376-84; PMID: 18765529; http://dx. doi. org/10. 1158/1078-0432. CCR-08-0455.